Fujirebio has announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems.
These chemiluminescent enzyme immunoassays allow for the quantitative measurement of neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes. The two assays are available for research use only.
The new biomarker tests will allow researchers and clinical research professionals across the world to further study the clinical utility of NfL in diverse neurodegenerative disease conditions such as multiple sclerosis, Parkinson's or Alzheimer's disease
“In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid line up of tests for the entire neurodegenerative disease field as quickly as possible.”
The new biomarker tests will allow researchers and clinical research professionals across the world to further study the clinical utility of NfL in diverse disease conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as in acute situations such as traumatic brain injury. NfL is considered a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies.
Laboratory professionals can select their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardised immunoassay system family is widely available and used in routine labs active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform meets the necessary throughput, quality, and regulatory requirements to support possible future routine use of NfL in addition to the existing portfolio.
